Jeffrey M. Leiden, an insider at Vertex Pharmaceuticals Inc (VRTX), purchased 87,807 shares of the company at a price of $86.52 per share, amounting to a total transaction value of $7.60 million on December 2, 2025. Following this transaction, Leiden holds 87,807 shares of Vertex.
This acquisition underscores insider confidence in Vertex Pharmaceuticals, a biotechnology company known for developing small molecule drugs for serious diseases. The company, headquartered in Boston, Massachusetts, has a market capitalization of $114.7 billion and a trailing P/E ratio of 31.21, with earnings per share reported at 14.23.
Vertex has seven approved medicines, including treatments for cystic fibrosis and severe sickle cell disease. The company's upcoming earnings report is scheduled for August 3, 2026, with estimates of $5.06 EPS and $3.3 billion in revenue.
Insider transactions, such as this one, provide transparency into executive sentiment regarding company performance. However, investors are advised to consider multiple data points and trends in insider activity rather than making decisions based on isolated transactions.